Skip to main content

Table 1 Baseline characteristics of patients divided by BMI, LMI, and BF tertiles

From: The influence of body composition on the N-terminal pro-B-type natriuretic peptide level and its prognostic performance in patients with acute coronary syndrome: a cohort study

 

BMI strata

LMI strata

BF strata

Tertile 1

Tertile 2

Tertile 3

P value

Tertile 1

Tertile 2

Tertile 3

P value

Tertile 1

Tertile 2

Tertile 3

P value

N

546

539

538

 

541

542

540

 

541

541

541

 

Age, year (IQR)

69 (60–74)

66 (58–72)

65 (56–72)

<0.001

71 (64–85)

66 (59–72)

61 (58–68)

<0.001

62 (55–70)

67 (59–73)

69 (62–74)

<0.001

Female, n (%)

121 (22.2)

123 (22.8)

119 (22.1)

0.96

121 (22.4)

122 (22.5)

120 (22.2)

1.00

121 (22.4)

121 (22.4)

121 (22.4)

1.00

Diagnosis, n (%)

   

0.112

   

0.232

   

0.079

 AMI

242 (44.3)

219 (40.6)

205 (38.1)

 

238 (44.0)

215 (39.7)

213 (39.4)

 

243 (44.9)

213 (39.4)

210 (38.8)

 

 UA

304 (55.7)

320 (59.4)

333 (61.9)

 

303 (56.0)

327 (60.3)

327 (60.6)

 

298 (55.1)

328 (60.6)

331 (61.2)

 

BMI, kg/m2 (IQR)

21.6 (20.3–22.4)

24.1 (23.5–24.7)

27.0 (26.0–28.4)

<0.001

21.6 (20.3–22.5)

24.1 (23.4–24.8)

26.9 (26.0–28.4)

<0.001

21.6 (20.3–22.8)

24 (23.1–24.9)

26.8 (25.7–28.4)

<0.001

LMI, kg/m2 (IQR)

16.4 (14.7–17.0)

17.8 (17.2–18.2)

19.0 (18.3–19.7)

<0.001

16.4 (14.7–17.0)

17.9 (17.5–18.2)

19.0 (18.6–19.7)

<0.001

16.6 (15.0–17.5)

17.5 (16.4–18.3)

18.7 (17.5–19.6)

<0.001

BF, % (IQR)

24.3 (21.3–26.2)

26.3 (24.8–28.5)

30.0 (28.5–34.7)

<0.001

24.3 (22.0–27.2)

26.7 (24.5–29.5)

30.0 (27.5–34.7)

<0.001

23.0 (21.3–24.1)

26.1 (25.2–27.2)

30.1 (28.6–34.8)

<0.001

Heart rate, per minute (IQR)

73 (65–82)

73 (65–82)

73 (65–82)

0.627

75 (65–84)

72 (65–82)

73 (65–82)

0.320

73 (65–82)

73 (65–82)

73 (65–82)

0.967

Systolic blood pressure, mmHg (IQR)

127 (110–143)

130 (115–145)

132 (120–146)

<0.001

128 (110–144)

130 (115–145)

130 (118–145)

0.081

124.5 (110–140)

130 (116–146)

134 (120–148)

<0.001

Diastolic blood pressure, mmHg (IQR)

74 (66–82)

75 (70–83)

79 (70–88)

<0.001

72 (65–82)

75 (70–82)

80 (70–89)

<0.001

74 (68–84)

75 (68–84)

78 (70–86)

0.017

Previous MI, n (%)

135 (24.8)

141 (26.4)

141 (26.6)

0.764

139 (25.8)

130 (24.1)

148 (27.7)

0.405

147 (27.2)

131 (24.4)

139 (26.0)

0.574

Previous PCI, n (%)

42 (7.7)

38 (7.1)

42 (7.8)

0.873

41 (7.6)

42 (7.8)

39 (7.3)

0.951

36 (6.7)

43 (8.0)

43 (8.0)

0.656

Previous heart failure, n (%)

26 (4.8)

27 (5.1)

39 (7.3)

0.149

31 (5.8)

27 (5.0)

34 (6.3)

0.639

22 (4.1)

24 (4.5)

46 (8.6)

0.002

Medical history

 Previous CVD, n (%)

21 (3.9)

15 (2.8)

16 (3.0)

0.571

24 (4.4)

14 (2.6)

14 (2.6)

0.141

13 (2.4)

23 (4.3)

16 (3.0)

0.207

 Hypertension, n (%)

264 (49.4)

286 (54.0)

320 (60.2)

0.002

271 (51.0)

307 (57.4)

292 (55.0)

0.110

232 (43.8)

285 (53.7)

353 (65.9)

<0.001

 Type 1 or 2 diabetes mellitus, n (%)

109 (20.3)

134 (25.1)

131 (24.5)

0.125

118 (22.1)

140 (25.9)

116 (21.7)

0.199

103 (19.4)

124 (23.0)

147 (27.4)

0.008

 Current smoking, n (%)

80 (15.4)

84 (16.5)

81 (15.8)

0.886

67 (13.1)

85 (16.6)

93 (18.0)

0.084

98 (19.1)

85 (16.6)

62 (12.1)

0.008

 Dyslipidemia, n (%)

62 (12.3)

81 (16.8)

105 (21.6)

<0.001

53 (10.6)

83 (17.2)

112 (22.7)

<0.001

70 (14.1)

76 (15.5)

102 (21.0)

0.01

Laboratory values

 Total cholesterol, mmol/L (IQR)

4.0 (3.4–4.7)

4.0 (3.4–4.9)

4.0 (3.4–4.8)

0.509

3.9 (3.3–4.6)

4.0 (3.4–4.9)

4.0 (3.4–5.0)

0.021

4.0 (3.4–4.8)

4.0 (3.4–4.8)

4.0 (3.4–4.8)

0.917

 eGFR, ml/min (IQR)

76.4 (60.8–90.5)

78.2 (62.5–91.8)

77.8 (61.7–91.2)

0.627

72.9 (56.9–86.7)

78.3 (63.6–92.3)

80.7 (64.5–94.1)

<0.001

82.8 (68.5–96.0)

77.3 (61.7–90.6)

73.2 (57.3–85.9)

<0.001

 LVEF, % (IQR)

61 (51–68)

62 (51–67)

64 (53–69)

0.017

61 (50–68)

62 (52–68)

64 (53–68)

0.179

61 (51–67)

63 (51–68)

64 (54–68)

0.014

 LVEDV, ml (IQR)

101 (83–120)

104 (89–127)

109 (93–129)

<0.001

103 (83–123)

103 (90–124)

108 (92–129)

0.002

102 (83–124)

103 (88–124)

108 (93–128)

0.005

 Troponin >100 upper limit of normal, n (%)

135 (25.2)

130 (24.7)

115 (22.0)

0.409

139 (26.2)

120 (22.7)

121 (23.0)

0.324

136 (25.7)

129 (34.3)

115 (21.9)

0.341

Clinical severity of ACS

 Killip >1, n (%)

101 (18.5)

104 (19.3

85 (15.8

0.292

101 (18.7)

105 (19.4)

84 (15.6)

0.219

101 (18.7)

96 (17.7)

93 (17.2)

0.814

 TIMI score

   

<0.001

   

<0.001

   

<0.001

  Low risk, n (%)

41 (7.5)

98 (18.2)

168 (31.2)

 

24 (4.4)

80 (14.8)

203 (37.6)

 

79 (14.6)

105 (19.4)

123 (22.7)

 

  Medium risk, n (%)

189 (34.6)

204 (37.9)

198 (36.8)

 

161 (29.8)

222 (41.0)

208 (38.5)

 

229 (42.3)

171 (31.6)

191 (35.3)

 

  High risk, n (%)

316 (57.9)

237 (44.0)

172 (32.0)

 

356 (65.8)

240 (44.3)

129 (23.9)

 

233 (43.1)

265 (49.0)

227 (42.0)

 

Angiographic and interventional data

 Three vessel disease, n (%)

174 (33.4)

147 (28.7)

157 (30.5)

0.258

179 (34.8)

157 (30.1)

142 (27.7)

0.043

158 (30.8)

148 (28.6)

172 (33.2)

0.280

 Left main disease, n (%)

65 (12.5)

55 (10.7)

59 (11.5)

0.681

68 (13.2)

55 (10.5)

56 (10.9)

0.345

53 (10.3)

59 (11.4)

67 (12.9)

0.422

 One or two vessel disease, n (%)

313 (60.1)

337 (65.8)

327 (63.5)

0.157

300 (58.4)

342 (65.5)

335 (65.4)

0.024

330 (64.3)

332 (64.2)

315 (60.8)

0.412

 No. of stents implanted (SD)

1.9 (1.1)

1.9 (1.1)

1.9 (1.1)

0.912

1.9 (1.2)

1.9 (1.1)

1.8 (1.1)

0.221

1.8 (1.1)

1.8 (1.1)

1.9 (1.1)

0.162

Medications at discharge, n (%)

 Aspirin

503 (92.6)

505 (95.1)

500 (93.1)

0.203

495 (92.2)

512 (95.3)

501 (93.3)

0.099

502 (93.5)

505 (94.2)

501 (93.1)

0.747

 Clopidogrel

497 (91.5)

500 (94.2)

497 (92.6)

0.246

490 (91.3)

506 (94.2)

498 (92.7)

0.170

502 (93.5)

498 (92.9)

494 (91.8)

0.567

 Statin

490 (90.2)

487 (91.9)

491 (91.4)

0.613

484 (90.1)

494 (92.2)

489 (91.2)

0.500

491 (91.4)

487 (91.0)

490 (91.1)

0.968

 ACEI/ARB

303 (55.9)

302 (57.0)

319 (59.5)

0.469

306 (57.1)

317 (59.3)

301 (56.1)

0.557

287 (53.5)

313 (58.4)

324 (60.5)

0.064

 Beta-blocker

334 (61.6)

336 (63.3)

378 (70.5)

0.005

325 (60.6)

348 (64.9)

375 (69.8)

0.007

334 (62.3)

341 (63.6)

373 (69.5)

0.033

 CCB

112 (20.7)

137 (25.9)

170 (31.7)

<0.001

117 (21.9)

146 (27.3)

156 (29.1)

0.020

102 (19.1)

137 (25.7)

180 (33.5)

<0.001

 Nitrate

228 (42.1)

234 (44.2)

250 (46.6)

0.319

238 (44.4)

235 (43.9)

239 (44.6)

0.975

203 (37.9)

252 (47.2)

257 (47.9)

0.001

  1. ACEI angiotensin-converting enzyme inhibitors; ACS acute coronary syndrome; AMI acute myocardial infarction; ARB angiotensin receptor bloker; BF body fat; BMI body mass index; CCB Calcium channel blockers; eGFR estimated glomerular filtration rate; IQR interquartile; LMI lean mass index; LVEF left ventricular ejection fraction; LVEDV left ventricular end-diastolic volume; MI myocardial infarction; TIMI thrombolysis in myocardial infarction; UA unstable angina